By SPC News Staff
The FDA expanded the approval of the COVID-19 drug remdesivir (Veklury, Gilead) to include pediatric patients 28 days of age and older, weighing at least 3 kg, with positive results from direct SARS-CoV-2 viral testing, who are hospitalized or who are not hospitalized but at high risk for progression to severe COVID-19.
Remdesivir is now the first approved COVID-19 treatment for children younger than 12 years of age. Previously, remdesivir was only approved to treat certain